Novartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) Book value per share
Novartis AG's book value per share at the end of fiscal 2025 was 24.0×, up 9.79% from 21.9× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 19.8×. Over the past ten years it has ranged from 21.9× (fiscal 2024) to 33.9× (fiscal 2018); the current reading is higher than 27% of that period. Novartis AG ranks 8th of 21 Drug Manufacturers General companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 24.0× | 9.79% |
| FY2024 | 21.9× | (2.85%) |
| FY2023 | 22.5× | (17.39%) |
| FY2022 | 27.2× | (9.89%) |
| FY2021 | 30.2× | 21.50% |
| FY2020 | 24.9× | 2.63% |
| FY2019 | 24.2× | (28.54%) |
| FY2018 | 33.9× | 7.25% |
| FY2017 | 31.6× | 0.30% |
| FY2016 | 31.5× | (1.72%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 19.8× | (10.02%) |
| Jun 2026 | 22.0× | 7.98% |
| Mar 2026 | 20.4× | (15.06%) |
| Dec 2025 | 24.0× | 3.32% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| JNJ Johnson & Johnson compare | 33.8× |
| AZN AstraZeneca PLC compare | 33.4× |
| AMGN Amgen Inc. compare | 26.5× |
| NVS Novartis AG | 19.8× |
| MRK Merck & Co., Inc. compare | 17.0× |
| PFE Pfizer Inc. compare | 15.7× |
| GILD Gilead Sciences, Inc. compare | 10.4× |
| NVO Novo Nordisk A/S compare | 7.8× |
| ABBV AbbVie Inc. compare | −2.6× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on NVS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement